

www.ispor.org



Changing Paradigm in the Evaluation of the Value of Medical Devices: What Must Stakeholders Expect in the New Decade?

Michael Drummond (Moderator)
Øyvind Melien
Rabia Kahveci
Yves Verboven

Issue Panel, ISPOR Europe,
Barcelona. November 12, 2018

Introduction to the Issue

- In most European countries, medical devices have not been subject to HTA as often as pharmaceuticals
- They have, however, been subject to procurement practices within health care systems
- Assessment of value should be an important feature of both HTA and procurement practices
- The relative lack of clinical evidence and the incremental nature of innovation poses challenges for value assessment for medical devices
- Proposed developments in HTA within the EU and efforts to improve procurement practices suggest that the paradigm is changing for the value assessment of medical devices

Topics for Discussion

- Which methodologies and innovative approaches are emerging in assessing the value of medical devices?
- What are the expectations of different stakeholders?
- What are the practical challenges and the potential solutions?

Our Panelists

- **Øyvind Melien, MD,PhD** Director of Reviews and HTA, Norwegian Institute of Public Health, Oslo, Norway
- **Rabia Kahveci, MD,MSc**, Associate Professor and Director of ANHTA, Ankara, Turkey
- **Yves Verboven**, Director of Market Access and Economic Policies, MedTech Europe, Brussels, Belgium